• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today

    8/5/22 5:23:39 PM ET
    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email

    GAINERS:

    • GH Research (NASDAQ:GHRS) shares closed up 29.83% at $15.80
    • Numinus Wellness (OTC:NUMIF) shares closed up 16.20% at $0.26
    • Cybin (AMEX:CYBN) shares closed up 14.94% at $0.71
    • Compass Pathways (NASDAQ:CMPS) shares closed up 14.69% at $20.07
    • ATAI Life Sciences (NASDAQ:ATAI) shares closed up 6.57% at $4.38
    • Revive Therapeutics (OTC:RVVTF) shares closed up 4.63% at $0.36
    • Seelos Therapeutics (NASDAQ:SEEL) shares closed up 2.84% at $1.00
    • Field Trip Health (NASDAQ:FTRP) shares closed up 1.12% at $0.84

    LOSERS:

    • Mind Medicine (NASDAQ:MNMD) shares closed down 12.15% at $0.62
    • Allied (OTC:ALID) shares closed down 0.00% at $0.52
    • Biomind Labs (OTC:BMNDF) shares closed down 0.00% at $0.75

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATAI
    $CMPS
    $CYBN
    $FTRP

    CompanyDatePrice TargetRatingAnalyst
    AtaiBeckley Inc.
    $ATAI
    1/20/2026$11.00Buy
    Guggenheim
    COMPASS Pathways Plc
    $CMPS
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    Mind Medicine (MindMed) Inc.
    $MNMD
    10/13/2025$28.00Buy
    Needham
    GH Research PLC
    $GHRS
    10/13/2025$19.00Buy
    Needham
    AtaiBeckley Inc.
    $ATAI
    10/13/2025$12.00Buy
    Needham
    Mind Medicine (MindMed) Inc.
    $MNMD
    8/4/2025$25.00Outperform
    Oppenheimer
    AtaiBeckley Inc.
    $ATAI
    7/29/2025$14.00Outperform
    Oppenheimer
    COMPASS Pathways Plc
    $CMPS
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtaiBeckley To Host Virtual Investor Day on March 6, 2026

    NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company's executive leadership team and several external key opinion leaders. Investors, analysts, and members of the media are invited to register for the live webcast. A replay will be made available following the event on the investor

    2/20/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways Announces Pricing of $150 Million Public Offering

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares ("ADSs") at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the

    2/18/26 8:18:00 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Apeiron Investment Group Ltd. bought $19,000,000 worth of shares (8,675,799 units at $2.19) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    8/18/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $2,520,000 worth of shares (1,800,000 units at $1.40) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    3/24/25 5:00:18 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Apeiron Investment Group Ltd. bought $22,755,008 worth of shares (10,835,718 units at $2.10) (SEC Form 4)

    4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

    2/19/25 6:00:05 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on AtaiBeckley with a new price target

    Guggenheim initiated coverage of AtaiBeckley with a rating of Buy and set a new price target of $11.00

    1/20/26 9:22:21 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COMPASS Pathways upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00

    12/10/25 8:10:44 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on MindMed with a new price target

    Needham initiated coverage of MindMed with a rating of Buy and set a new price target of $28.00

    10/13/25 8:54:29 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 16,181 units of Ordinary Shares, decreasing direct ownership by 7% to 205,121 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    2/3/26 5:19:56 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sullivan Mark sold $148,244 worth of shares (11,276 units at $13.15), decreasing direct ownership by 4% to 282,576 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/29/25 5:00:03 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Barrow Robert sold $339,072 worth of shares (25,791 units at $13.15), decreasing direct ownership by 3% to 778,477 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/29/25 5:00:06 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    SEC Filings

    View All

    COMPASS Pathways Plc filed SEC Form 8-K: Regulation FD Disclosure

    8-K - COMPASS Pathways plc (0001816590) (Filer)

    2/19/26 8:50:58 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by COMPASS Pathways Plc

    424B5 - COMPASS Pathways plc (0001816590) (Filer)

    2/19/26 8:49:57 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by COMPASS Pathways Plc

    424B5 - COMPASS Pathways plc (0001816590) (Filer)

    2/17/26 4:08:59 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Financials

    Live finance-specific insights

    View All

    AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression

    A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically meaningful antidepressant effects that were sustained for up to eight weeksPatients who received an active dose of BPL-003 in the core study of the Phase 2b clinical trial (either 8 mg or 12 mg) met response and remission criteria for depression at increased rates after receiving a 12 mg dose in the OLE study, with 63% in response and 48% in remission at Week 8 in the OLE study (Week 16 of the Phase 2b clinical trial)An End-of-Phase 2 meeting has been scheduled with the U.S. Food

    11/10/25 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

    Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/698442687. The webcast will be archived for 30 days. About Compass Pathways Compass Pathw

    10/28/25 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Leadership Updates

    Live Leadership Updates

    View All

    AtaiBeckley Appoints Michael Faerm as Chief Financial Officer

    NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investment banking. As Chief Financial Officer at AtaiBeckley, he will lead the Company's financial strategy, capital markets activities, and overall financial operations. Anne Johnson, who ha

    2/19/26 7:00:00 AM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATAI
    $CMPS
    $CYBN
    $FTRP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care